Expertise in
38
conditions

Dr. Julio Hajdenberg

Oncology
New England Cancer Specialists
2 Independence Dr, 
Kennebunk, ME 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
38
conditions
New England Cancer Specialists
2 Independence Dr, 
Kennebunk, ME 

Overview

Julio Hajdenberg is an Oncologist in Kennebunk, Maine. Dr. Hajdenberg is highly rated in 38 conditions, according to our data. His top areas of expertise are Reticulohistiocytoma, Histiocytosis, Factor 5 Deficiency, Prostate Cancer, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in ME

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

New England Cancer Specialists
2 Independence Dr, Kennebunk, ME 04043
Other Locations
Office
130 S Huntington Ave, Boston, MA 02130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 7 Less Clinical Trials

16 Total Publications

Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.
Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.
Journal: Cureus
Published: March 29, 2022
Similar Doctors
Expertise in
24
conditions
Dr. Peter Westervelt
Oncology
Expertise in
24
conditions
Dr. Peter Westervelt
Oncology

Hematology & Oncology

329 Maine St # E101, 
Brunswick, ME 
 (121.8 miles away)
207-373-2266
Languages Spoken:
English
See accepted insurances

Peter Westervelt is an Oncologist in Brunswick, Maine. Dr. Westervelt is highly rated in 24 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Colonoscopy.

Expertise in
42
conditions
Dr. Christian Thomas
Oncology
Expertise in
42
conditions
Dr. Christian Thomas
Oncology

New England Cancer Specialists - Rock Row

11 Rock Row Ste 120, 
Westbrook, ME 
 (101.9 miles away)
207-303-3300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christian Thomas is an Oncologist in Westbrook, Maine. Dr. Thomas is highly rated in 42 conditions, according to our data. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Lung Cancer, and Nephrectomy.

Expertise in
20
conditions
Dr. Leslie Bradford
Oncology
Expertise in
20
conditions
Dr. Leslie Bradford
Oncology

Office

100 Campus Dr Ste 125, 
Scarborough, ME 
 (94.1 miles away)
207-883-0069
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Bradford is an Oncologist in Scarborough, Maine. Dr. Bradford is highly rated in 20 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Salpingo-Oophorectomy, and Oophorectomy.

Frequently Asked Questions about Dr. Julio Hajdenberg

How do I make an appointment with Dr. Julio Hajdenberg?

You can book an appointment with Dr. Julio Hajdenberg by calling their office at 207-303-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julio Hajdenberg a top-rated expert for Reticulohistiocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julio Hajdenberg is classified as an Advanced expert for Reticulohistiocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julio Hajdenberg specialize in?

While Dr. Julio Hajdenberg is a Oncology, they have specific expertise in Reticulohistiocytoma, Histiocytosis, and Factor 5 Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Julio Hajdenberg participate in research or clinical trials?

Yes. Dr. Julio Hajdenberg has published 16 articles and abstracts on conditions like Reticulohistiocytoma. You can view a list of Dr. Julio Hajdenberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julio Hajdenberg accept my insurance?

Dr. Julio Hajdenberg accepts most major insurance plans, including Aetna. We recommend calling the office directly at 207-303-3300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hajdenberg's expertise for a condition
ConditionClose
      View All 38 Advanced Conditions
      View All 100 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile